retatrutide and heart rate Issues: Cardiovascular Effects, Risks, and Safety – Bolt Pharmacy Understanding the Link: Arrhythmias &

Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for two distinct indications: type 2 diabetes mellitus (marketed as Mounjaro) and chronic weight management (marketed as Zepbound)

WADA, for example, is funding a trial to test how semaglutide changes runners body composition and performance

How do GLP-1 injections promote fat loss

For the right patient, they produce 1520% weight loss alongside meaningful improvements in blood sugar, blood pressure, cholesterol, and even cardiovascular outcomes

Competition in the GLP-1 sector is never about elimination, but about leveraging respective strengths to advance the development of metabolic disease treatments